Chiesi Archives -

Switch data back Chiesi/Protalix long-acting Fabry drug

https://pharmaphorum.com/news/switch-data-back-chiesi-protalix-long-acting-fabry-drug/

Moderna broadens R&D scope with Vertex, Chiesi alliances

https://pharmaphorum.com/news/moderna-broadens-rd-scope-with-vertex-chiesi-alliances/

Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021

https://pharmaphorum.com/news/chiesis-flagship-fabry-drug-heads-for-fda-verdict-in-early-2021/

Chiesi ups its focus on rare diseases

https://pharmaphorum.com/r-d/views-analysis-r-d/chiesi-ups-its-focus-on-rare-diseases/

Chiesi starts rare diseases division, ahead of potential Fabry disease filing

https://pharmaphorum.com/news/chiesi-starts-rare-diseases-division-as-fabry-treatment/

FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK

https://pharmaphorum.com/news/fda-rejection-scuppers-azs-hopes-of-a-copd-triple-clash-with-gsk/

Verona to take COPD hopeful into phase 3

https://pharmaphorum.com/market-access-2/verona-to-take-copd-hopeful-into-phase-3/

Europe: thumbs up for Roche’s Hemlibra, Chiesi rare disease drug, bad news for Santhera

https://pharmaphorum.com/news/roches-haemophilia-drug-poised-hit-eu-market/

COPD triple approved, can GSK maximise its revenues?

https://pharmaphorum.com/news/gsk-launch-copd-triple-therapy-us/

Search